The 19th edition of China Association of Clinical Laboratory Practice Expo (CACLP) will take place from 27-29 March 2022 at the Nanchang Greenland International Expo Center under the show theme of “Brand Makes Future Glory".
The 2nd China IVD Supply Chain Expo (CISCE), co-located with CACLP, is set to focus on raw materials, distribution and logistics in the in vitro diagnostic industry. CACLP and CISCE will join forces to create the highest-quality business community, serving the entire IVD industry globally.
As the largest in vitro diagnostic exhibition and congress in China, CACLP has been committed to building an international platform which integrates manufacturing, academy, research, application, education and management over the past three decades. The expo will feature a range of manufacturers, agencies, organizations, institutions, investment partners and other organisations relevant to IVD, as well as entrepreneurs, scholars, professionals and other practitioners, with the principle of creating lasting relationships.
In 2021, CACLP hosted 1,188 exhibiting companies and 38,346 professional visitors with a growth of 18% and 9% respectively. The exhibiting space in Chongqing last year was 80,500, an increase of 15% over CACLP 2020. In the upcoming CACLP 2022, the exhibit space will be expanded 50% to 120,000+m2 in Nanchang. More than 1,400 exhibitors and 40,000+ professional visitors from different countries and regions are expected to gather to see the latest developments in technology, foster relationships with current partners and meet new customers.
The outbreak of COVID-19 epidemic in 2020 has had a vital impact on the global in vitro diagnostic industry. The market volume of COVID-19 testing products has surged, with a huge market demand for nucleic acid testing products and antibody testing products, which has driven the rapid development of testing products. Since 2020, 15 IVD-related companies have been newly listed in the Chinese market. Currently, there are 47 listed companies mainly engaged in in vitro diagnostics, covering production, trade, and third-party medical testing. In vitro diagnostics is currently the largest and fastest growing segment of the medical device industry; its Chinese market size has reached 150 billion CNY in 2020.
"According to the latest news from the National Health Commission of the People’s Republic of China, the total number of medical and health institutions in China has exceeded one million. In the past few decades, the primary medical market, dominated by county-level hospitals, has also continued to rise. The government has made a huge investment to build laboratories of medical and health institutions across the country. These laboratories need new products with clear targeting indications, reliable quality and universal application scenarios to meet the needs of diagnosis and treatment urgently.
Therefore, equipment configuration has become its top priority.” Said Professor Song Haibo, vice chairman of the National Association of Health Industry and Enterprises Management, chairman of the China Association of In Vitro Diagnostics. “The epidemic has greatly increased the importance of laboratories and diagnosis to medical institutions in various regions and has also provided opportunities for further increasing the market share of both domestic and international companies."
Alongside the main exhibition, five conferences and forums will run at the Primus Hotel Nanchang International Expo City, including the 9th China IVD Industry Development Conference (CIIDC), the 7th China Experimental Medicine Conference (CEMC), Enlightening Lab Med - the 5th IVD Youth Entrepreneur Forum (ELMY), the 4th China IVD Distribution Enterprise Forum (CIDEF) and the 2nd China Key Raw Material & Parts Forum. With the cooperation of the National Association of Health Industry and Enterprises Management, China Association of In Vitro Diagnostics (CAIVD) and Professional Community of Experimental Medicine (PCEM), and Shanghai Academy of Experimental Medicine, these conferences will be complemented by academic seminars: Pathology, Blood Transfusion, Diagnostics, Supervision and over 100 business thematic activities.
Meanwhile, the online and live events have been designed to allow participants to use their time more effectively and efficiently through CACLP. The online platform will be available for a month after the event to allow visitors to continue to acquire information and make connections in the in vitro diagnostic industry.
For more information, please visit: http://en.caclp.com
Contact for press:
Ms. Tiki WANG
tiki.wang@gl-events.com
Tel: +86 21 5255 8215
